Table S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Abstract
Pharmacokinetic parameters for utomilumab in combination with rituximab (Cycle 1)